• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: How to Evaluate CA19-9 Response to Neoadjuvant Treatment for Resectable Pancreatic Cancer?: Reduced Value or Reduction Rate?

作者信息

Motoi Fuyuhiko, Ashitomi Yuya

机构信息

Department of Surgery I, Yamagata University Faculty of Medicine, Yamagata, Japan.

出版信息

Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18169-w.

DOI:10.1245/s10434-025-18169-w
PMID:40890544
Abstract
摘要

相似文献

1
ASO Author Reflections: How to Evaluate CA19-9 Response to Neoadjuvant Treatment for Resectable Pancreatic Cancer?: Reduced Value or Reduction Rate?ASO作者反思：如何评估可切除胰腺癌新辅助治疗的CA19-9反应？：降低的值还是降低率？
Ann Surg Oncol. 2025 Sep 1. doi: 10.1245/s10434-025-18169-w.
2
ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.ASO作者反思：优化可切除胰腺癌的治疗：CA19-9>500 U/mL作为新辅助治疗的生物学指标
Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17458-8.
3
Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.CA19-9大于500 U/mL的可切除胰腺癌：强化新辅助化疗生存获益的生物学指标
Ann Surg Oncol. 2025 May 13. doi: 10.1245/s10434-025-17407-5.
4
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.在两项随机试验中，基线血清碳水化合物抗原 19-9 水平对可切除和交界可切除胰腺癌患者新辅助放化疗治疗效果的预测价值。
Br J Surg. 2023 Sep 6;110(10):1374-1380. doi: 10.1093/bjs/znad210.
5
Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradiotherapy.新辅助治疗后CA19-9值对胰腺癌预后的影响：与新辅助放化疗相比，新辅助化疗后的影响更为显著。
Pancreatology. 2025 Jun 28. doi: 10.1016/j.pan.2025.06.016.
6
ASO Author Reflections: The Landmark Series-Neoadjuvant Therapy for Resectable Pancreatic Cancer.ASO作者反思：里程碑系列——可切除胰腺癌的新辅助治疗
Ann Surg Oncol. 2025 Sep;32(9):6571-6572. doi: 10.1245/s10434-025-17835-3. Epub 2025 Jul 10.
7
ASO Author Reflections: Comparison Between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer.ASO作者反思：可切除胰腺癌患者新辅助放化疗与化疗的比较
Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18116-9.
8
ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis.ASO作者反思：辅助治疗对接受新辅助化疗的胰腺癌患者有生存获益吗？一项CA19-9分析。
Ann Surg Oncol. 2020 Oct;27(10):3961-3962. doi: 10.1245/s10434-020-08542-2. Epub 2020 May 5.
9
Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.可切除边缘胰腺癌患者的新辅助治疗：反应率和切除率的系统评价与荟萃分析
Pancreatology. 2016 Jan-Feb;16(1):28-37. doi: 10.1016/j.pan.2015.11.007. Epub 2015 Dec 2.
10
Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Gemcitabine: A Retrospective Cohort Study.S-1与吉西他滨治疗的可切除胰腺癌患者新辅助化疗后糖类抗原19-9水平的预后意义：一项回顾性队列研究
World J Oncol. 2025 Jun;16(3):269-275. doi: 10.14740/wjon2563. Epub 2025 Jun 14.

本文引用的文献

1
Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal Adenocarcinoma.根据糖类抗原19-9水平改变化疗方案的新辅助治疗用于可切除/交界可切除胰腺导管腺癌
Ann Surg Oncol. 2025 Jan;32(1):517-528. doi: 10.1245/s10434-024-16361-y. Epub 2024 Oct 21.
2
Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.术后血清糖类抗原19-9水平持续升高是根治性切除的胰腺腺癌患者原发性肝复发的高风险特征。
World J Surg. 2019 Feb;43(2):634-641. doi: 10.1007/s00268-018-4814-4.
3
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.
2017 年国际胰腺导管腺癌边界可切除定义和标准的共识。
Pancreatology. 2018 Jan;18(1):2-11. doi: 10.1016/j.pan.2017.11.011. Epub 2017 Nov 22.